A phase I/II study of the combination of 5-azacytidine [azacitidine] with valproic acid and all-trans retinoic acid [tretinoin] in patients with high risk myelodysplastic syndrome and acute myelogenous leukaemia.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Azacitidine (Primary) ; Tretinoin; Valproic acid
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2012 Actual patient number changed from 55 to 34 as reported by ClinicalTrials.gov. (NCT00326170).
- 14 Jun 2012 Actual patient number changed from 55 to 34 as reported by ClinicalTrials.gov. (NCT00326170).
- 11 Aug 2009 Actual end date (1 Dec 2007) added as reported by ClinicalTrials.gov.